ClinicalTrials.gov
public full text
Public Domain
NR in Chemo-induced Peripheral Neuropathy
The purpose of this single-arm phase II trial is to determine whether nicotinamide riboside (NIAGEN®) prevents the progression of peripheral sensory neuropathy in patients receiving infusions of paclitaxel or nab-paclitaxel for the treatment of metastatic breast cancer or recurrent platinum-resistant ovarian, endometrial, peritoneal, fallopian tube cancer or metastatic head and neck cancer.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- NIAGEN and Persistent Chemotherapy-Induced Peripheral Neuropathy#1377492
- Preliminary Safety Analysis of Two Pilot Clinical Trials Involving Injections of Niagen (R), Nicotinamide Riboside Chloride#238051
- Efficacy of Metformin as Preventive Treatment in Paclitaxel Induced Peripheral Neuropathy in Breast Cancer Patients#162438
- Nicotinamide Riboside for Diabetic Neuropathy#893680
- The CONTRoL Trial: Cryotherapy vs. cOmpression Neuropathy TRiaL#1430003
Record · ID 1430838
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive